首页> 外文期刊>The economist >A vaxxing problem
【24h】

A vaxxing problem

机译:vaxxing问题

获取原文
获取原文并翻译 | 示例
           

摘要

LAST WEEK, the billionth dose of covid-19 vaccine was made. It is a sign of how greatly capacity has expanded over the past six months that the next billion could be produced by May 27th, according to Airfin-ity, an analytics firm (see chart on next page). Yet this ambition is at risk from American export controls on raw materials and equipment. Production lines in India, turning out at least 160m doses of covid vaccine a month, will soon grind to a halt unless America supplies 37 critical items. On April 16th Adar Poonawalla, head of the world's biggest vaccine-maker, the Serum Institute of India (SII), begged President Joe Biden, in a tweet, to "lift the embargo of raw material exports out of the us...Your administration has the details". Suresh Jadhav, sn's executive director, says that in the next four to six weeks manufacturing of two vaccines will be affected: As-traZeneca's, of which sn makes 100m doses a month, and Novavax's, of which it expects to make 6om-7om doses a month, SII says it first alerted the American government about this two months ago.
机译:上周,制造了亿分儿科疫苗疫苗。根据Airfin-Ity,Airfin-Ity,Airfin-Ity(参见下一页的图表),这是在过去的六个月内扩展的迹象表明,在过去的六个月内,在5月27日可以在5月27日之前生产。然而,这场野心面临着美国出口管制对原材料和设备的风险。在印度生产线,每月减少至少160米的苍白疫苗,除非美国提供37项关键项,否则将很快磨损到停止。 4月16日ADAR Poonawalla是世界上最大的疫苗制造商,印度血清研究所(SII),乞讨Joe Biden的总统,在推文中乞求“将原料出口禁止抵消美国......你的管理有细节“。 SN的执行董事Suresh Jadhav表示,在接下来的四到六周的制造中,两个疫苗将受到影响:As-Trazeneca的制造,其中SN为每月100米的剂量,其中它预计将预期为60M-7M剂量一个月,SII表示,这是两个月前提醒美国政府。

著录项

  • 来源
    《The economist》 |2021年第9242期|共2页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号